<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303171</url>
  </required_header>
  <id_info>
    <org_study_id>MIE1</org_study_id>
    <nct_id>NCT02303171</nct_id>
  </id_info>
  <brief_title>Use of Warfarin After the First Trimester in Pregnant Women With APS</brief_title>
  <official_title>Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohamed Sayed Abdelhafez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of
      using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with
      antiphospholipid syndrome (APS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will be randomly divided into two groups; one will be subjected to anticoagulant
      therapy by Enoxaparin throughout pregnancy and the other will be subjected to anticoagulant
      therapy by Enoxaparin in the first trimester then Warfarin after the first trimester until
      termination of pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal loss</measure>
    <time_frame>From 12 weeks to 42 weeks gestational age</time_frame>
    <description>Unexplained fetal death of morphologically normal fetus after the first trimester</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>From 20 weeks to 34 weeks gestational age</time_frame>
    <description>Delivery of morphologically normal fetus before 34 weeks of gestation due to severe preeclampsia or placental insufficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine growth restriction (IUGR)</measure>
    <time_frame>At birth</time_frame>
    <description>Birth weight less than the 10th percentile for gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital fetal malformations</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hemorrhagic complications</measure>
    <time_frame>After 12 weeks gestational age up to birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>After 12 weeks gestational age up to birth</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Recurrent Miscarriage</condition>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Enoxaparin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)</description>
    <arm_group_label>Enoxaparin group</arm_group_label>
    <other_name>Clexan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy</description>
    <arm_group_label>Warfarin group</arm_group_label>
    <other_name>Marevan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women with APS diagnosed according to the revised classification criteria for
             APS in 2006 in Sydney, Australia

          -  Early pregnancy body weight is 50-90 Kg

        Exclusion Criteria:

          -  Women with systemic lupus erythematosus (SLE)

          -  Women with active thromboembolic disorders

          -  Women with history of previous thromboembolic disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed I Eid, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed S Abdelhafez, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed M Badawy, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdelmageed F Mashaly, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed I Eid, Dr</last_name>
    <phone>+201225401274</phone>
    <email>dr_moh_eid@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Department in Mansoura University Hospital</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed I Eid, Dr</last_name>
      <phone>+201225401274</phone>
      <email>dr_moh_eid@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private practice settings</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2014</study_first_submitted>
  <study_first_submitted_qc>November 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mohamed Sayed Abdelhafez</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Antiphospholipid syndrome</keyword>
  <keyword>APS</keyword>
  <keyword>Warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

